Market Failure in Public Health

Market failure in public health occurs when private exchange does not allocate healthcare in the quantity or manner that maximises social welfare. For essential medicines, market allocation can fail across innovation, availability, affordability and appropriate use because patients have weak choice, suppliers may possess market power, and benefits or costs may spill over to others.

Information, uncertainty and weak consumer choice

Healthcare transactions are characterised by uncertainty and information asymmetry.

• Patients often cannot judge the diagnosis, necessity, quality or substitutes for a medicine; providers can influence demand while advising or treating them.
• Urgency and lifesaving need make demand less responsive to price and impede comparison shopping, so high prices may exclude patients without reducing medical need.
• Uncertain illness creates demand for insurance, whose markets face adverse selection; coverage can generate moral hazard when users bear only part of the treatment cost.

Market power and wider social effects

Essential-medicine markets may not produce competitive prices or socially desirable consumption.

• Patent exclusivity encourages research and development but temporarily restricts competition; limited therapeutic substitutes or concentrated supply can consequently create market power.
• Vaccination produces positive externalities because reduced transmission benefits others, making its social marginal benefit greater than its private marginal benefit.
• Disease surveillance, health information and epidemic control provide collective benefits that individual purchasers cannot fully capture or finance.

Affordability and public policy

Allocation based only on purchasing power can be inequitable and, where externalities or information failures exist, inefficient.

• Tax financing, subsidies, free provision, insurance and collective procurement can lower user costs and move consumption towards the socially efficient level; government need not manufacture every medicine or deliver every service itself.
• In India, the National List of Essential Medicines identifies medicines considered essential for priority healthcare needs, while the Drugs (Prices Control) Order, 2013 provides for ceiling prices of scheduled formulations administered by the National Pharmaceutical Pricing Authority.
• Regulation and consumer protection can address quality, pricing and information problems, while insurance regulation can mitigate selection-related failures.
• Intervention must consider effectiveness, safety, cost and distributional effects. Reliable supply chains, credible information, proportionality and informed consent remain important because lower prices alone may not ensure access or appropriate use.